Information Journal Paper
APA:
Copy. (2018). Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 141(6), 2142-2155. SID. https://sid.ir/paper/763683/en
Vancouver:
Copy. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY[Internet]. 2018;141(6):2142-2155. Available from: https://sid.ir/paper/763683/en
IEEE:
Copy, “Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations,” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 141, no. 6, pp. 2142–2155, 2018, [Online]. Available: https://sid.ir/paper/763683/en